Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply

Lancet Oncol. 2017 May;18(5):e244. doi: 10.1016/S1470-2045(17)30261-9.

Authors

Elizabeth C Smyth¹, William H Allum², Samuel Rowley³, Ruth E Langley³, David Cunningham¹

Affiliations

¹ Department of Oncology, Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
² Department of Oncology, Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK; Department of Surgery, Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
³ Medical Research Council Clinical Trials Unit, University College London, London, UK.

PMID: 28495289
DOI: 10.1016/S1470-2045(17)30261-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Adenocarcinoma*
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab*
Colorectal Neoplasms
Humans

Substances

Bevacizumab

Grants and funding